Advertisement

Tumor Biology

, Volume 35, Issue 3, pp 2473–2480 | Cite as

Prognostic value of circulating tumor cells in patients with pancreatic cancer: a meta-analysis

Research Article

Abstract

Increasing scientific evidences suggest that circulating tumor cells (CTC) in peripheral blood may be a powerful predictor of survival in patients with pancreatic cancer. However, many existing studies have yielded inconclusive results. This meta-analysis aims to assess the prognostic value of CTC in patients with pancreatic cancer. An extensive literary search for relevant studies was conducted on PubMed, Embase, Web of Science, Cochrane Library, CISCOM, CINAHL, Google Scholar, CNKI, and CBM databases from their inception through July 1, 2013. The meta-analysis was then performed using the Stata 12.0 software. Crude hazard ratios (HRs) with 95 % confidence intervals (CIs) were calculated under a fixed or random effect model. Nine cohort studies were included in this meta-analysis with a total of 623 pancreatic cancer patients. This number included 268 CTC-positive patients and 355 CTC-negative patients. Our meta-analysis revealed that patients in the CTC-positive group were significantly associated with poor progression-free survival (PFS) (HR = 1.89, 95 % CI = 1.25–4.00, P < 0.001). Furthermore, pancreatic cancer patients in the CTC-positive group also showed worse overall survival (OS) than those in the CTC-negative group (HR = 1.23, 95 % CI = 0.88–2.08, P < 0.001). Subgroup analysis by ethnicity indicated that CTC-positive patients had poor OS among both Asian and Caucasian populations (all P < 0.05). Further subgroup analyses by detection and treatment methods also suggested that CTC-positive patients showed worser OS than CTC-negative patients in the majority of subgroups (all P < 0.05). No publication bias was detected in this meta-analysis. In conclusion, our meta-analysis suggests that CTC-positive pancreatic cancer patients may have worser PFS and OS than CTC-negative patients. Detection of CTC in peripheral blood may be a promising biomarker for the detection and prognosis of pancreatic cancer.

Keywords

Circulating tumor cells Pancreatic cancer Prognosis Biomarker 

Notes

Acknowledgments

This research is funded by Science and Technology Commission of Shanghai Municipality (No. 134119a6800).

Conflicts of interest

None.

References

  1. 1.
    Maisonneuve P, Lowenfels AB. Epidemiology of pancreatic cancer: an update. Dig Dis. 2010;28:645–56.PubMedCrossRefGoogle Scholar
  2. 2.
    Raimondi S, Maisonneuve P, Lowenfels AB. Epidemiology of pancreatic cancer: an overview. Nat Rev Gastroenterol Hepatol. 2009;6:699–708.PubMedCrossRefGoogle Scholar
  3. 3.
    Li D, Abbruzzese JL. New strategies in pancreatic cancer: emerging epidemiologic and therapeutic concepts. Clin Cancer Res. 2010;16:4313–8.PubMedCentralPubMedCrossRefGoogle Scholar
  4. 4.
    Lucas AL, Chang MM, Lipsyc MD, Frucht H. The prevention and genetics of pancreatic cancer: a programmatic approach. Methods Mol Biol. 2013;980:205–14.PubMedCentralPubMedCrossRefGoogle Scholar
  5. 5.
    Pantel K, Alix-Panabieres C. Circulating tumour cells in cancer patients: challenges and perspectives. Trends Mol Med. 2010;16:398–406.PubMedCrossRefGoogle Scholar
  6. 6.
    Khoja L, Backen A, Sloane R, Menasce L, Ryder D, et al. A pilot study to explore circulating tumour cells in pancreatic cancer as a novel biomarker. Br J Cancer. 2012;106:508–16.PubMedCentralPubMedCrossRefGoogle Scholar
  7. 7.
    Coghlin C, Murray GI. Current and emerging concepts in tumour metastasis. J Pathol. 2010;222:1–15.PubMedCrossRefGoogle Scholar
  8. 8.
    Nguyen DX, Bos PD, Massague J. Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer. 2009;9:274–84.PubMedCrossRefGoogle Scholar
  9. 9.
    Bidard FC, Huguet F, Louvet C, Mineur L, Bouche O, et al. Circulating tumor cells in locally advanced pancreatic adenocarcinoma: the ancillary CirCe 07 study to the LAP 07 trial. Ann Oncol. 2013;24:2057–61.PubMedCrossRefGoogle Scholar
  10. 10.
    de Albuquerque A, Kubisch I, Breier G, Stamminger G, Fersis N, et al. Multimarker gene analysis of circulating tumor cells in pancreatic cancer patients: a feasibility study. Oncology. 2012;82:3–10.PubMedCrossRefGoogle Scholar
  11. 11.
    Hu L, Zhou JH, Yu ZQ, Yi YX, Ding H, et al. [Clinical significance of h-TERT and c-Met expression in the peripheral blood circulation of pancreatic cancer patients]. Chinese J Clin Oncol. 2013;40:208–11.Google Scholar
  12. 12.
    Soeth E, Grigoleit U, Moellmann B, Roder C, Schniewind B, et al. Detection of tumor cell dissemination in pancreatic ductal carcinoma patients by CK 20 RT-PCR indicates poor survival. J Cancer Res Clin Oncol. 2005;131:669–76.PubMedCrossRefGoogle Scholar
  13. 13.
    Uchikura K, Takao S, Nakajo A, Miyazono F, Nakashima S, et al. Intraoperative molecular detection of circulating tumor cells by reverse transcription-polymerase chain reaction in patients with biliary-pancreatic cancer is associated with hematogenous metastasis. Ann Surg Oncol. 2002;9:364–70.PubMedCrossRefGoogle Scholar
  14. 14.
    Stang A. Critical evaluation of the newcastle-ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25:603–5.PubMedCrossRefGoogle Scholar
  15. 15.
    Jackson D, White IR, Riley RD. Quantifying the impact of between-study heterogeneity in multivariate meta-analyses. Stat Med. 2012;31:3805–20.PubMedCentralPubMedCrossRefGoogle Scholar
  16. 16.
    Biggerstaff BJ, Jackson D. The exact distribution of Cochran's heterogeneity statistic in one-way random effects meta-analysis. S Stat Med. 2008;27:6093–110.CrossRefGoogle Scholar
  17. 17.
    Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. Comparison of two methods to detect publication bias in meta-analysis. JAMA. 2006;295:676–80.PubMedCrossRefGoogle Scholar
  18. 18.
    Hirooka S, Yanagimoto H, Satoi S, Yamamoto T, Toyokawa H, et al. The role of circulating dendritic cells in patients with unresectable pancreatic cancer. Anticancer Res. 2011;31:3827–34.PubMedGoogle Scholar
  19. 19.
    Kurihara T, Itoi T, Sofuni A, Itokawa F, Tsuchiya T, et al. Detection of circulating tumor cells in patients with pancreatic cancer: a preliminary result. J Hepatobiliary Pancreat Surg. 2008;15:189–95.PubMedCrossRefGoogle Scholar
  20. 20.
    Sergeant G, Roskams T, van Pelt J, Houtmeyers F, Aerts R, et al. Perioperative cancer cell dissemination detected with a real-time RT-PCR assay for EpCAM is not associated with worse prognosis in pancreatic ductal adenocarcinoma. BMC Cancer. 2011;11:47.PubMedCentralPubMedCrossRefGoogle Scholar
  21. 21.
    Riethdorf S, Fritsche H, Muller V, Rau T, Schindlbeck C, et al. Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the Cell Search system. Clin Cancer Res. 2007;13:920–8.PubMedCrossRefGoogle Scholar
  22. 22.
    Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004;351:781–91.PubMedCrossRefGoogle Scholar
  23. 23.
    Hou JM, Greystoke A, Lancashire L, Cummings J, Ward T, et al. Evaluation of circulating tumor cells and serological cell death biomarkers in small cell lung cancer patients undergoing chemotherapy. Am J Pathol. 2009;175:808–16.PubMedCentralPubMedCrossRefGoogle Scholar
  24. 24.
    Sequist LV, Nagrath S, Toner M, Haber DA, Lynch TJ. The CTC-chip: an exciting new tool to detect circulating tumor cells in lung cancer patients. J Thorac Oncol. 2009;4:281–3.PubMedCrossRefGoogle Scholar
  25. 25.
    Stott SL, Lee RJ, Nagrath S, Yu M, Miyamoto DT, et al. Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer. Sci Transl Med. 2010;2:25ra23.PubMedCentralPubMedCrossRefGoogle Scholar
  26. 26.
    Cohen SJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, et al. Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. Ann Oncol. 2009;20:1223–9.PubMedCrossRefGoogle Scholar
  27. 27.
    Nakamura S, Yagata H, Ohno S, Yamaguchi H, Iwata H, et al. Multi-center study evaluating circulating tumor cells as a surrogate for response to treatment and overall survival in metastatic breast cancer. Breast Cancer. 2010;17:199–204.PubMedCrossRefGoogle Scholar
  28. 28.
    Maestro LM, Sastre J, Rafael SB, Veganzones SB, Vidaurreta M, et al. Circulating tumor cells in solid tumor in metastatic and localized stages. Anticancer Res. 2009;29:4839–43.PubMedGoogle Scholar
  29. 29.
    McGauran N, Wieseler B, Kreis J, Schuler YB, Kolsch H, et al. Reporting bias in medical research - a narrative review. Trials. 2010;11:37.PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2013

Authors and Affiliations

  1. 1.Economics Division, School of Social and International StudiesUniversity of BradfordBradfordUK
  2. 2.Department of Radiology, Tongji HospitalTongji UniversityShanghaiChina
  3. 3.Tongji Hospital, School of MedicineTongji UniversityShanghaiChina

Personalised recommendations